Ticker: ZBIO

Zenas BioPharma, Inc. (NASDAQ: ZBIO) - quick read on what's happening inside The company is executing an expensive, accelerated clinical and pre-commercial build for its lead drug obexelimab while monetizing regional rights (Zai, Tenacia, BMS). Cash and liquid securities are healthy today, but bu...

**Zenas BioPharma, Inc. (NASDAQ: ZBIO) Overview** Financial Highlights (3 months ended March 31, 2025): Total Revenue: $10.0 million (up from $0 in the same period last year) Net Loss: $33.6 million (compared to $27.8 million loss in Q1 2024) Operating Expenses: $47.3 million (compared to $27.6 ...